Neogen Chemicals Approves Preferential Issue of ₹161 Crore, Calls EGM for March 29
Neogen Chemicals approved a preferential issue of 10,00,000 equity shares at ₹1,610 per share, raising ₹161 Crore. An EGM is scheduled for March 29, 2026, to seek shareholder approval. Cadamba Solutions Private Limited is the proposed allottee.
The preferential issue of ₹161 Crore represents a significant capital raise, which could impact the company's financial structure and potentially fund expansion or strategic projects. The dilution for existing shareholders is moderate.
The company is undertaking a preferential issue to raise capital, which is generally seen as a positive development for funding growth or strategic initiatives.
Neogen Chemicals Limited announced the outcome of its Board Meeting held on March 7, 2026. The Board approved the issuance of 10,00,000 equity shares of face value ₹10 each at a price of ₹1,610 per share, including a premium of ₹1,600 per share. This preferential issue aggregates to ₹1,61,00,00,000 (₹161 Crore) and is subject to shareholder and regulatory approvals.
The company also approved the convening of an Extra Ordinary General Meeting (EGM) of its members on Sunday, March 29, 2026, at 11:30 a.m. via video conferencing. The EGM is to seek shareholder approval for the preferential issue. The record date for determining eligibility for remote e-voting and attending the EGM is Friday, March 20, 2026. The Register of Members and Share Transfer Register will be closed from Saturday, March 21, 2026, to Sunday, March 29, 2026.
The preferential issue will be to Cadamba Solutions Private Limited, a promoter group entity, which will receive 10,00,000 equity shares. Post-allotment, Cadamba Solutions Private Limited will hold 3.65% of the company's equity. The issue price of ₹1,610 per share is 17.02% above the calculated floor price of ₹1,375.82. The equity shares issued will be subject to an 18-month lock-in period.
What to do with a filing like this
Neogen Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Neogen Chemicals Limited. Read the original for the full detail.